ArticleBMC veterinary research2025
Screening and characterization of monoclonal antibodies with neutralizing activity against porcine transmissible gastroenteritis virus.
Article in BMC veterinary research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundPorcine Transmissible Gastroenteritis Virus (TGEV) is widespread and frequently involved in co-infections, leading to high mortality rates in piglets and significantly constraining the swine industry. Based on the genetic sequence of TGEV strain HB-1, we designed and constructed a eukaryotic expression plasmid, pCAGGS-TGEV-CTD, encoding the CTD gene of TGEV. The recombinant CTD protein was successfully expressed and purified using the HEK-293 F suspension cell expression system. Balb/c mice were immunized with the purified CTD protein.
resultsUpon achieving a serum antibody titer of 10⁵, antigen-specific memory B cells were isolated using single-cell flow cytometry sorting. A total of 83 matched antibody light- and heavy-chain gene pairs were obtained via single-cell RT-PCR. These gene pairs were cloned into pCAGGS eukaryotic expression vectors containing murine constant light (CL) and heavy (CH) chain regions, resulting in the construction of 42 recombinant plasmids for antibody expression. Following transfection into HEK-293T cells, antibody supernatants were harvested at 48 h post-transfection. ELISA screening identified 18 antibodies reactive to the TGEV CTD protein, five high-titer antibodies were confirmed to cross-react with TGEV virions through indirect immunofluorescence assay (IFA). Further neutralization assays demonstrated that all five monoclonal antibodies exhibited in vitro neutralizing activity, effectively inhibiting TGEV infection and replication in swine testicular (ST) cells.
conclusionThis study successfully generated TGEV-specific antibodies, providing critical support for fundamental research on TGEV research and the development of clinical diagnostic reagents.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.